title: Understanding risk and enhancing safety in immunotherapy trials.
authors.forename: Deepali
authors.initials: D
authors.lastname: Kumar
authors.forename: Atul
authors.initials: A
authors.lastname: Humar
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000077561:Daclizumab; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D020031:Epstein-Barr Virus Infections / Q000209:etiology*; D005260:Female; D006566:Herpesviridae Infections / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid